This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Thursday's Health Winners & Losers

Cortex has inactivated but hasn't formerly withdrawn the IND while it reviews the FDA response but said any resubmission for ADHD is unlikely. The company is also studying CX717 for acute treatment of respiratory depression and for Alzheimer's Disease. Cortex noted that an acute indication requiring a lower dose or an indication with a different risk/benefit profile would be a better fit for the drug. Shares tumbled $1.14, or 63%, to 66 cents.

On the rising side, Novacea (NOVC) edged up 11 cents, or 1.7%, to $8.60, after initiating a phase II, 56-patient trial for banoxantrone, an investigational anti-cancer prodrug in patients with relapsed or refractory acute lymphoblastic leukemia (ALL), a type of cancer that starts with white blood cells in the bone marrow.

The primary efficacy objective is the response rate over three cycles of the drug, and the secondary efficacy objectives are duration of response and overall survival. The study will also evaluate safety and tolerability.

Also, Momenta (MNTA) climbed after disclosing top-line results from a phase I study and announcing that it treated the first patient in its phase II study (called the Eminence trial) on the IV formulation of its blood thinner M118. The study is designed to treat patients with stable coronary artery disease who are undergoing percutaneous coronary intervention (PCI). Shares rose 63 cents, or 5%, to $13.08.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,378.17 +115.61 0.71%
S&P 500 1,857.32 +14.34 0.78%
NASDAQ 4,074.5990 +40.4380 1.00%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs